Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

@article{HenaoRestrepo2015EfficacyAE,
  title={Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial},
  author={Ana Maria Henao-Restrepo and Ira M. Longini and Matthias Egger and Natalie E. Dean and W. John Edmunds and Anton Camacho and Miles W. Carroll and Moussa Doumbia and Bertrand Draguez and S. Duraffour and Godwin C. Enwere and Rebecca F. Grais and Stephan Gunther and Stefanie Hossmann and Mandy Kader Kond{\'e} and Souleymane Kon{\'e} and Eeva Kuisma and Myron M. Levine and Sema Mandal and Gunnstein Norheim and Ximena Riveros and Aboubacar Soumah and Sven Trelle and Andrea Vicari and Conall H. Watson and Sakoba K{\'e}{\"i}ta and Marie Paule Kieny and John-Arne R{\o}ttingen},
  journal={The Lancet},
  year={2015},
  volume={386},
  pages={857-866}
}

Figures and Tables from this paper

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
TLDR
RVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy, and glycoprotein-binding antibody titers were sustained through 180 days in all participants.
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
TLDR
In this phase 1 study of healthy volunteers, immunization with Ad26.ZEBOV or MVA-BN-Filo did not result in any vaccine-related serious adverse events, and an immune response was observed after primary immunization, which resulted in sustained elevation of specific immunity.
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
TLDR
The data indicate that the vaccine is safe and induces strong humoral and cellular immune response in up to 100 % of healthy adult volunteers, and provide a rationale for testing efficacy in Phase III trials.
Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice.
TLDR
The results suggest that BALB/c mice can be used to evaluate the effectiveness of Ad5-EBOV, and that the cellular immune response and humoral immune response can be use as indicators to evaluate vaccine effectiveness.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
TLDR
This Ebola vaccine candidate elicited anti‐Ebola antibody responses and these results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
TLDR
RVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy, and glycoprotein-binding antibody titers were sustained through 180 days in all participants.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
TLDR
This Ebola vaccine candidate elicited anti‐Ebola antibody responses and these results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses.
Chimpanzee Adenovirus Vector Ebola Vaccine
Background The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international response to accelerate the availability of a preventive vaccine. A replication‐defective recombinant
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
TLDR
The chimpanzee adenovirus 3 (ChAd3) vaccine boosted with MVA elicited B-cell and T-cell immune responses to ZEBOV that were superior to those induced by the ChAd3 vaccine alone.
The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola
TLDR
The protocol for a novel cluster randomised controlled trial design which uses ring vaccination of individuals at high risk of infection due to their social or geographical connection to a known case is described.
Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus
TLDR
An immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species is developed.
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
TLDR
A single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus.
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates
TLDR
It is indicated that CD8+ cells have a major role in rAd5-GP–induced immune protection against Ebola virus infection in NHPs, as depletion of CD8+, in vivo using the cM-T807 monoclonal antibody (mAb), abrogated protection in four out of five subjects.
Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections.
TLDR
Analysis of data on 3343 confirmed and 667 probable Ebola cases collected in Guinea, Liberia, Nigeria, and Sierra Leone as of September 14 indicates that without drastic improvements in control measures, the numbers of cases and deaths from EVD are expected to continue increasing from hundreds to thousands per week in the coming months.
...
1
2
3
...